Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CyclopharmASX:CYC -1.79%39 EV-to-EBIT is -3.95 as of Jul. 23, 2026. GuruFocus rates ASX:CYC with a GF Score™ of 39/100 and a GF Value™ of A$0.83 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 94 Medical Distribution companies, Cyclopharm ranks worse than 1063828.72% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cyclopharm's Enterprise Value for the quarter that ended in Dec. 2025 was A$110.03 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-17.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm EV-to-EBIT Related Terms
Cyclopharm EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cyclopharm's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cyclopharm's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cyclopharm's EV-to-EBIT falls into.
Cyclopharm's current Enterprise Value is A$70.27 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-17.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a EV-to-EBIT of -3.95 as of Jul. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cyclopharm and its competitors. According to the industry distribution chart, Cyclopharm ranks #999999 out of 94 companies in the Medical Distribution industry.
Is Cyclopharm's EV-to-EBIT too high?
Cyclopharm's current EV-to-EBIT is -3.95. Based on the distribution chart, Cyclopharm ranks #999999 out of 94 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cyclopharm has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's EV-to-EBIT compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #999999 out of 94 companies for EV-to-EBIT. This places Cyclopharm in the lower half of its industry. The industry median EV-to-EBIT is 12.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 12.06, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cyclopharm and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 12.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current EV-to-EBIT is -3.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.83, compared to a current price of A$0.55 — trading 33.7% below its estimated fair value. The current EV-to-EBIT is -3.95. Cyclopharm's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current EV-to-EBIT is -3.95 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.55 is trading 33.7% below its estimated GF Value™ of A$0.83.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
EV-to-EBIT: -3.95
GF Value™: A$0.83 vs. price of A$0.55 (33.7% below fair value)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
39GF Score
Get the complete analysis for ASX:CYC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
